Trending:
News
-
18 June 2018
Novartis finds Jakavi can help real-world blood cancer patients
Novartis has reported positive data from a real-world comparison study of its Jakavi (ruxolitinib) drug conducted to treat patients with polycythemia vera (PV), a rare incurable blood cancer.
-
18 June 2018
FDA approves Suboxone generic variant to treat opioid dependence
The US Food and Drug Administration (FDA) has granted Mylan Technologies and Dr. Reddy's Laboratories marketing approval for generic versions of Suboxone (buprenorphine and naloxone) sublingual film to treat opioid...
-
15 June 2018
Johnson & Johnson sells LifeScan to Platinum Equity
Global pharmaceutical company Johnson & Johnson has accepted investment firm Plantinum Equity’s offer to acquire LifeScan, its blood glucose monitoring business, for approximately $2.1bn.
-
15 June 2018
Sage and Shionogi to advance depression drug in Asia
US-based biopharmaceutical Sage Therapeutics has partnered with Japanese pharmaceutical firm Shionogi over clinical development and commercialisation of its drug candidate, SAGE-217.
-
15 June 2018
Deals and M&As this week: Alexion Pharmaceuticals, Recipharm, AstraZeneca
Alexion Pharmaceuticals has partnered with Complement Pharma for the co-development of pre-clinical complement inhibitor for neurodegenerative disorders.
-
15 June 2018
Merck’s Keytruda gets US approval for PMBC lymphoma
Merck has received the US Food and Drug Administration (FDA) approval for the use of its Keytruda drug to treat refractory primary mediastinal large B-cell lymphoma (PMBCL).
-
14 June 2018
FDA fast-tracks Nordic Nanovector’s Betalutin for follicular lymphoma
Norwegian biotechnology firm Nordic Nanovector has secured fast-track status from the US Food and Drug Administration (FDA) for its Betalutin (177Lu-lilotomab satetraxetan) drug to treat follicular lymphoma (FL).
-
14 June 2018
Eisai to set up dementia research facility in US
Japanese pharmaceutical company Eisai is set to open a new exploratory research facility in Cambridge, Massachusetts, US to identify new drugs for the treatment of dementia.
-
14 June 2018
UK’s NICE issues positive guidance for Janssen’s Tremfya
The National Institute for Health and Care Excellence (NICE) of the UK has issued positive guidance for Janssen Pharmaceutical’s Tremfya (guselkumab) to treat adults suffering from moderate to severe plaque...
-
13 June 2018
FDA suggests new reimbursement idea for antimicrobial drugs
The US Food and Drug Administration (FDA) has published a statement from its commissioner Scott Gottlieb proposing a new reimbursement model for antibiotics and antimicrobials, which it believes will help...
